German pharma firm buys €80m C3 to boost its European cannabis presence

This story examines the significance of German pharma group Dermapharm’s acquisition of the Germany based Cannabinoid Compound Company (C3) from Canadian owner Canopy Growth. We show how it’s an opportunity for Dermapharm to expand in the European medical cannabis market, but represents a considerable loss for Canopy after only three years’ ownership.


Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Erik Galavis
+34 654 320 547
Email Erik

Pablo Sharrock
+34 722 642 678
Email Pablo